Pitofenone hydrochloride, a spasmolytic compound, inhibits the acetylcholinesterase (AChE) activity from bovine erythrocytes and from electric eel with Kis of 36 and 45 μM, respectively.

Pitolisant is a potent, and selective nonimidazole inverse agonist at the recombinant human H3 receptor (Ki=0.16 nM).

Pitolisant is a potent, and selective nonimidazole inverse agonist at the recombinant human H3 receptor (Ki=0.16 nM).

Pitolisant is a potent, and selective nonimidazole inverse agonist at the recombinant human H3 receptor (Ki=0.16 nM).

Pivagabine has a highly significant therapeutic potential in clinical conditions characterized by manifestations of psychological distress due to an inadequate management of stressful events.

Pivagabine has a highly significant therapeutic potential in clinical conditions characterized by manifestations of psychological distress due to an inadequate management of stressful events.

Pivagabine has a highly significant therapeutic potential in clinical conditions characterized by manifestations of psychological distress due to an inadequate management of stressful events.

Pivmecillinam is an orally active prodrug of mecillinam, an extended-spectrum penicillin antibiotic.

Pivmecillinam is an orally active prodrug of mecillinam, an extended-spectrum penicillin antibiotic.

Pivmecillinam is an orally active prodrug of mecillinam, an extended-spectrum penicillin antibiotic.

Pivmecillinam is an orally active prodrug of mecillinam, an extended-spectrum penicillin antibiotic.

Pivalopril is an inhibitor of active angiotensin converting enzyme (ACE).

Pivalopril is an inhibitor of active angiotensin converting enzyme (ACE).

Pivalopril is an inhibitor of active angiotensin converting enzyme (ACE).

Pivalopril is an inhibitor of active angiotensin converting enzyme (ACE).

Pizotifen is a highly selective 5-HT receptor blocking agent, which is a benzocycloheptane based drug.

Pizotifen is a highly selective 5-HT receptor blocking agent, which is a benzocycloheptane based drug.

PJ34 is a potent specific inhibitor of PARPl/2 with IC50 of 110 nM and 86 nM, respectively.

PJ34 is a potent specific inhibitor of PARPl/2 with IC50 of 110 nM and 86 nM, respectively.

PJ34 is a potent specific inhibitor of PARPl/2 with IC50 of 110 nM and 86 nM, respectively.

PJ34 is a potent specific inhibitor of PARPl/2 with IC50 of 110 nM and 86 nM, respectively.

PK11195 is a 2‑Phenylindolylglyoxylyldipeptide Murine Double Minute2 (MDM2)/Translocator Protein (TSPO)/Human Constitutive Androstane Receptor (hCAR) Inhibitor, and is potentially useful for the Treatment of Gliomas.

PK11195 is a 2‑Phenylindolylglyoxylyldipeptide Murine Double Minute2 (MDM2)/Translocator Protein (TSPO)/Human Constitutive Androstane Receptor (hCAR) Inhibitor, and is potentially useful for the Treatment of Gliomas.

PK11195 is a 2‑Phenylindolylglyoxylyldipeptide Murine Double Minute2 (MDM2)/Translocator Protein (TSPO)/Human Constitutive Androstane Receptor (hCAR) Inhibitor, and is potentially useful for the Treatment of Gliomas.

PK11195 is a 2‑Phenylindolylglyoxylyldipeptide Murine Double Minute2 (MDM2)/Translocator Protein (TSPO)/Human Constitutive Androstane Receptor (hCAR) Inhibitor, and is potentially useful for the Treatment of Gliomas.

PKC-iota inhibitor 1 (compound 19) is a protein kinase C-iota (PKC-ι ℩) inhibitor with an IC50 value of 0.34 μM.

PKC-iota inhibitor 1 (compound 19) is a protein kinase C-iota (PKC-ι ℩) inhibitor with an IC50 value of 0.34 μM.

PKC-iota inhibitor 1 (compound 19) is a protein kinase C-iota (PKC-ι ℩) inhibitor with an IC50 value of 0.34 μM.

PKC-iota inhibitor 1 (compound 19) is a protein kinase C-iota (PKC-ι ℩) inhibitor with an IC50 value of 0.34 μM.

PKC-iota inhibitor 1 (compound 19) is a protein kinase C-iota (PKC-ι ℩) inhibitor with an IC50 value of 0.34 μM.

PKC-iota inhibitor 1 (compound 19) is a protein kinase C-iota (PKC-ι ℩) inhibitor with an IC50 value of 0.34 μM.